Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25518710 | 1.00 | LRRK2 (0.50) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL25199919 | 0.86 | LRRK2 (0.48) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL30347616 | 0.86 | LRRK2 (0.48) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL30348428 | 0.84 | LRRK2 (0.48) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL25156870 | 0.84 | LRRK2 (0.48) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL30346638 | 0.83 | LRRK2 (0.47) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL25206773 | 0.83 | LRRK2 (0.47) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL25197957 | 0.83 | LRRK2 (0.45) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL30347524 | 0.83 | LRRK2 (0.45) | LRRK2ROCK2ROCK1CDC42BPBJAK3 | |
| SCHEMBL30347624 | 0.80 | LRRK2 (0.53) | LRRK2ROCK2ROCK1CDC42BPBJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | claimed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | LRRK2 729/4885ROCK2 998/4885ROCK1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.